Search

Your search keyword '"Walter Noordzij"' showing total 3 results
Start Over Author "Walter Noordzij" Journal bmc cancer
3 results on '"Walter Noordzij"'

1. Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol

Author

Daan Andel, Marnix G. E. H. Lam, Joep de Bruijne, Maarten L. J. Smits, Arthur J. A. T. Braat, Adriaan Moelker, Erik Vegt, Simeon J. S. Ruiter, Walter Noordzij, Gianluca Grazi, Giulio E. Vallati, Roel J. Bennink, Otto M. van Delden, Onno W. Kranenburg, Jan N. M. Ijzermans, Maarten W. Nijkamp, Joris I. Erdmann, Rosa Sciuto, Jeroen Hagendoorn, and Inne H. M. Borel Rinkes

Subjects
Radiation lobectomy, Radioembolization, Holmium-166, 166Ho, Hepatocellular carcinoma, Unilobar radioembolization, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background High dose unilobar radioembolization (also termed ‘radiation lobectomy’)—the transarterial unilobar infusion of radioactive microspheres as a means of controlling tumour growth while concomitantly inducing future liver remnant hypertrophy—has recently gained interest as induction strategy for surgical resection. Prospective studies on the safety and efficacy of the unilobar radioembolization-surgery treatment algorithm are lacking. The RALLY study aims to assess the safety and toxicity profile of holmium-166 unilobar radioembolization in patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant. Methods The RALLY study is a multicenter, interventional, non-randomized, open-label, non-comparative safety study. Patients with hepatocellular carcinoma who are considered ineligible for surgery due to insufficiency of the future liver remnant (

Published
2023
Full Text
View/download PDF

2. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Author

Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, and James Nagarajah

Subjects
Hormone sensitive prostate Cancer, Lutetium-177-PSMA, Metastases directed therapy, Oligometastases, Radioligand therapy, Urologic oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). However, many patients do not qualify for these treatments due to prior interventions or tumor location. Such oligometastatic patients could benefit from radioligand therapy (RLT) with 177Lu-PSMA; a novel tumor targeting therapy for end-stage metastatic castration-resistant prostate cancer (mCRPC). Especially because RLT could be more effective in low volume disease, such as the oligometastatic status, due to high uptake of radioligands in smaller lesions. To test the hypothesis that 177Lu-PSMA is an effective treatment in oHSPC to prolong PFS and postpone the need for androgen deprivation therapy (ADT), we initiated a multicenter randomized clinical trial. This is globally, the first prospective study using 177Lu-PSMA-I&T in a randomized multicenter setting. Methods & design This study compares 177Lu-PSMA-I&T MDT to the current standard of care (SOC); deferred ADT. Fifty-eight patients with oHSPC (≤5 metastases on PSMA PET) and high PSMA uptake (SUVmax > 15, partial volume corrected) on 18F-PSMA PET after prior surgery and/or EBRT and a PSA doubling time of

Published
2020
Full Text
View/download PDF

3. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Author

Winald R. Gerritsen, Daniela E. Oprea-Lager, Constantijn H.J. Muselaers, Henk G. van der Poel, Marianne A. Jonker, Walter Noordzij, Marcel J.R. Janssen, Jelle O. Barentsz, Tom W. J. Scheenen, Inge M. van Oort, Michel de Groot, Niven Mehra, Wouter V. Vogel, Bastiaan M. Privé, J. Alfred Witjes, Patrik Zamecnik, Andries M. Bergman, Martin Gotthardt, J. Fred Verzijlbergen, André N. Vis, James Nagarajah, Epidemiology and Data Science, Internal medicine, Urology, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
Oncology, Male, Cancer Research, medicine.medical_treatment, Lutetium, urologic and male genital diseases, Metastases directed therapy, 030218 nuclear medicine & medical imaging, law.invention, Androgen deprivation therapy, Prostate cancer, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Study Protocol, 0302 clinical medicine, Randomized controlled trial, law, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Medicine, Outpatient clinic, Neoplasm Metastasis, Prospective cohort study, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Urologic oncology, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Disease Progression, Oligometastases, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.medical_specialty, Neoplasms, Hormone-Dependent, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Genetics, Humans, Progression-free survival, External beam radiotherapy, Adverse effect, Lutetium-177-PSMA, Radioisotopes, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Prostatic Neoplasms, Androgen Antagonists, Hormone sensitive prostate Cancer, medicine.disease, Hormones, Radioligand therapy, Quality of Life, Radiopharmaceuticals, business
Abstract

Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). However, many patients do not qualify for these treatments due to prior interventions or tumor location. Such oligometastatic patients could benefit from radioligand therapy (RLT) with 177Lu-PSMA; a novel tumor targeting therapy for end-stage metastatic castration-resistant prostate cancer (mCRPC). Especially because RLT could be more effective in low volume disease, such as the oligometastatic status, due to high uptake of radioligands in smaller lesions. To test the hypothesis that 177Lu-PSMA is an effective treatment in oHSPC to prolong PFS and postpone the need for androgen deprivation therapy (ADT), we initiated a multicenter randomized clinical trial. This is globally, the first prospective study using 177Lu-PSMA-I&T in a randomized multicenter setting. Methods & design This study compares 177Lu-PSMA-I&T MDT to the current standard of care (SOC); deferred ADT. Fifty-eight patients with oHSPC (≤5 metastases on PSMA PET) and high PSMA uptake (SUVmax > 15, partial volume corrected) on 18F-PSMA PET after prior surgery and/or EBRT and a PSA doubling time of 177Lu-PSMA-I&T at a 6-week interval. After both cycles, patients are monitored every 3 weeks (including adverse events, QoL- and xerostomia questionnaires and laboratory testing) at the outpatient clinic. Twenty-four weeks after cycle two an end of study evaluation is planned together with another 18F-PSMA PET and (whole body) MRI. Patients in the SOC arm are eligible to receive 177Lu-PSMA-I&T after meeting the primary study objective, which is the fraction of patients who show disease progression during the study follow up. A second primary objective is the time to disease progression. Disease progression is defined as a 100% increase in PSA from baseline or clinical progression. Discussion This is the first prospective randomized clinical study assessing the therapeutic efficacy and toxicity of 177Lu-PSMA-I&T for patients with oHSPC. Trial registration Clinicaltrials.gov identifier: NCT04443062.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results